Physician profile

Myron Scott Strickland

Obstetrics & Gynecology · Fayetteville, NC

NPI 1336189505

$4,022.59

in general payments reported to CMS, 2019-2025

41 companies · $258 in 2025

The $258 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).

See the full distribution for Obstetrics & Gynecology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,353.88
Education$88.34

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Stryker Corporation $818.28 2019-2023 1688
Daiichi Sankyo INC. $399.14 2019-2024 Injectafer
Pfizer INC. $331.55 2019-2024
Abbvie INC. $239.82 2019-2024 Liletta
Exeltis, USA INC. $180.54 2019-2025 Slynd
Ethicon US, LLC $175.49 2023-2025 Enseal X1, Echelon Circular, Surgicel Nu-Knit
Astellas Pharma US INC $149.95 2021-2024 Veozah
Organon LLC $144.04 2021-2025 Nexplanon
Coopersurgical, INC. $132.11 2019-2024 Paragard T 380a, Endosee
Exact Sciences Corporation $130.81 2023-2025 Cologuard Collection Kit
Novo Nordisk INC $130.61 2019-2023
Therapeuticsmd, INC. $124.48 2020-2022
Mayne Pharma Commercial LLC $113.61 2021-2025
Agile Therapeutics, INC. $97.81 2021-2024 Twirla
Evofem Biosciences, INC. $90.88 2021-2024
Show all 40 companies
CompanyGeneral paymentsYearsTop products
Bayer Healthcare Pharmaceuticals INC. $79.91 2020-2022
Hologic Sales and Service, LLC $75.85 2019-2025 Thinprep 2000 Processor, Aptima
Mission Pharmacal Company $67.48 2019-2021
Biogen, INC. $60.69 2025 Zurzuvae
Avion Pharmaceuticals $48.24 2020-2022
Shield Therapeutics INC $43.73 2023 Accrufer
Aspira Women'S Health INC $41.93 2022-2024 Ova1
Urovant Sciences INC $33.50 2022
Amag Pharmaceuticals, INC. $29.28 2019
Aroa Biosurgery Incorporated $25.61 2025
Lupin INC. $25.55 2019-2020
Dexcom, INC. $22.77 2023 Dexcom G6 Transmitter
Roche Diagnostics Corporation $19.82 2020
Lsi Solutions INC $19.51 2023 Running Device, Fornisee, Ti Knot
Myovant Sciences INC. $18.51 2022
Avanos Medical $18.31 2019
Mylan Pharmaceuticals INC. $17.35 2021
Pharmacosmos Therapeutics INC. $16.72 2023 Monoferric
Medtronic, INC. $15.19 2024 Interstim
Neos Therapeutics, LP $15.16 2021
Lilly USA, LLC $14.29 2024 Zepbound
Eagle Pharmaceuticals, INC. $14.24 2023
Esperion Therapeutics, INC. $13.90 2020
Millicent US INC $13.35 2024
Minerva Surgical, INC $12.58 2019

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Myron Scott Strickland

$4,022.59

in general payments reported 2019-2025

Years
2019-2025
Top company
Stryker Corporation
Context
The $258 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).

https://glasscript.com/doctor/241733/myron-scott-strickland

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.